Gapping up
In reaction to strong earnings/guidance: BSPM +17.2%, TZOO +13.8%, TGLS +12.1%, NFLX +11.3%, TCPI +6.9%, PM +5%, UN +4.2%, LFC +3.8%, UNH +3.1%, BX +3%, CPSS +2.8%, SHW +2.8%, UFPI +2.6%, GWW +1.7%, C +1.6%
Select metals/mining names showing strength: KGC +2.6%, HMY +2.5%, GOLD +2.2%, IGLD +1.5%, BHP +1.4%, RIO +0.7%, SLV +0.7%, GDX +0.5%
Other news: MNOV +33.6% (announces that FDA Grants Fast Track Designation for the co's MN-001 (tipelukast) for the Treatment of NASH with Fibrosis), INVE +28.5% (announced it has entered into an agreement with Cisco (CSCO) to provide solutions for the Internet of Everything), LLEX +16.8% (Wallington Investment Holdings discloses 22.1% active stake in 13D filing),CLRX +15.2% (CollabRx and Medytox Solutions (MMMS) have entered into a definitive merger agreement), PNRA +10.4% (increased share repurchase authorization to $750 mln; authorized $500 mln of new debt to repurchase shares; signed letter of intent to sell and refranchise 73 company-owned cafes; also upgraded to Mkt Perform from Underperform at Raymond James), ONCY +8.9% (cont strength), NBY +8.4% (announces signing a distribution agreement with AmerisourceBergen for Avenova), AEZS +7.1% (files additional patent application to strengthen IP protection of Zoptarelin Doxorubicin), TCPI +6.9% (announced that Ellis Yan has decided not to renew his employment agreement as CEO contract to expire on June 30, 2015), MCP +4.2% (cont strength), MDCO +4.1% (FDA Advisory Committee votes 9 yes, 2 no, 1 abstain to recommend approval of cangrelor injection), MNGA +3.9% (Signs JV for Major Expansion of Subsidiary), OMED +3.8% (announced the presentation of Demcizumab data from its Phase 1B clinical trial to treat non-small cell lung cancer), STEM +3.1% (nnounces it has completed transplanting the six patients comprising the first cohort of its Phase II Pathway Study), CRH +2.4% (benefitting from Lafarge/Holcim deal moving fwd), VVUS +2% (files lawsuit against Teva (TEVA) for infringement of Qsymia patents), RPRX +1.8% (announces November 30, 2015 PDUFA goal date for NDA), CNHI +1.7% (cont strength), ALLT +1.5% (receives four orders from Tier-1 operators to enable delivery of Security-as-a-Service and comply with regulation), ATRS +1.4% (has settled all litigation between Antares and Medac Pharma, Inc. and its parent, medac GmbH), AZN +0.9% (AstraZeneca's MedImmune and Immunocore announce that they have entered into a second collaboration)
Analyst comments: FOMX +2.6% (initiated with a Buy at Guggenheim), DATA +1.6% (initiated with a Buy at Stifel), COH +1.3% (upgraded to Overweight from Equal Weight at Barclays), BJRI +0.9% (initiated with a Buy at Guggenheim), LOW +0.9% (upgraded to Overweight from Neutral at Piper Jaffray)
In reaction to strong earnings/guidance: BSPM +17.2%, TZOO +13.8%, TGLS +12.1%, NFLX +11.3%, TCPI +6.9%, PM +5%, UN +4.2%, LFC +3.8%, UNH +3.1%, BX +3%, CPSS +2.8%, SHW +2.8%, UFPI +2.6%, GWW +1.7%, C +1.6%
Select metals/mining names showing strength: KGC +2.6%, HMY +2.5%, GOLD +2.2%, IGLD +1.5%, BHP +1.4%, RIO +0.7%, SLV +0.7%, GDX +0.5%
Other news: MNOV +33.6% (announces that FDA Grants Fast Track Designation for the co's MN-001 (tipelukast) for the Treatment of NASH with Fibrosis), INVE +28.5% (announced it has entered into an agreement with Cisco (CSCO) to provide solutions for the Internet of Everything), LLEX +16.8% (Wallington Investment Holdings discloses 22.1% active stake in 13D filing),CLRX +15.2% (CollabRx and Medytox Solutions (MMMS) have entered into a definitive merger agreement), PNRA +10.4% (increased share repurchase authorization to $750 mln; authorized $500 mln of new debt to repurchase shares; signed letter of intent to sell and refranchise 73 company-owned cafes; also upgraded to Mkt Perform from Underperform at Raymond James), ONCY +8.9% (cont strength), NBY +8.4% (announces signing a distribution agreement with AmerisourceBergen for Avenova), AEZS +7.1% (files additional patent application to strengthen IP protection of Zoptarelin Doxorubicin), TCPI +6.9% (announced that Ellis Yan has decided not to renew his employment agreement as CEO contract to expire on June 30, 2015), MCP +4.2% (cont strength), MDCO +4.1% (FDA Advisory Committee votes 9 yes, 2 no, 1 abstain to recommend approval of cangrelor injection), MNGA +3.9% (Signs JV for Major Expansion of Subsidiary), OMED +3.8% (announced the presentation of Demcizumab data from its Phase 1B clinical trial to treat non-small cell lung cancer), STEM +3.1% (nnounces it has completed transplanting the six patients comprising the first cohort of its Phase II Pathway Study), CRH +2.4% (benefitting from Lafarge/Holcim deal moving fwd), VVUS +2% (files lawsuit against Teva (TEVA) for infringement of Qsymia patents), RPRX +1.8% (announces November 30, 2015 PDUFA goal date for NDA), CNHI +1.7% (cont strength), ALLT +1.5% (receives four orders from Tier-1 operators to enable delivery of Security-as-a-Service and comply with regulation), ATRS +1.4% (has settled all litigation between Antares and Medac Pharma, Inc. and its parent, medac GmbH), AZN +0.9% (AstraZeneca's MedImmune and Immunocore announce that they have entered into a second collaboration)
Analyst comments: FOMX +2.6% (initiated with a Buy at Guggenheim), DATA +1.6% (initiated with a Buy at Stifel), COH +1.3% (upgraded to Overweight from Equal Weight at Barclays), BJRI +0.9% (initiated with a Buy at Guggenheim), LOW +0.9% (upgraded to Overweight from Neutral at Piper Jaffray)